stella
beta
Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old — Stella
Recruiting
Back to Meningococcal Infections trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
South Korea
The Catholic University of Eunpyeong St.Mary's Hospital, Seoul
View full record on ClinicalTrials.gov